Source:http://linkedlifedata.com/resource/pubmed/id/15986078
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2005-6-29
|
pubmed:abstractText |
Actinic keratoses (AKs) are premalignant inflammatory skin lesions with the potential to transform into squamous cell carcinoma (SCC). There are several treatment options available for patients presenting with multiple AKs. Imiquimod is believed to stimulate and enhance host immune responses locally against skin tumors and viral infections. Five clinical studies to date have demonstrated its safety and efficacy in the treatment of actinic keratoses. Long-term follow-up studies examining recurrence rates are limited.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1201-5989
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
10
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1-6
|
pubmed:meshHeading | |
pubmed:year |
2005
|
pubmed:articleTitle |
Imiquimod 5% cream for the treatment of actinic keratoses.
|
pubmed:affiliation |
Division of Dermatology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
|
pubmed:publicationType |
Journal Article
|